CCL2 and breast cancer: Similar to previous observations, participants in the current feasibility study exhibited an increase in BMI (Supplementary Figure 6A), a reduction in physical activity (Supplementary Figure 6B), increases in the circulating pro-inflammatory cytokines BAFF, GDF-15, and MCP-1 and a decrease in IL-10 during chemotherapy for BC (Fig. 2).